Ophthotech Corp (NASDAQ:OPHT) major shareholder Svlsf Iv, Llc sold 1,966,935 shares of the company’s stock on the open market in a transaction dated Wednesday, June 4th. The stock was sold at an average price of $42.54, for a total value of $83,673,414.90. Following the completion of the transaction, the insider now directly owns 84,325 shares in the company, valued at approximately $3,587,186. Ophthotech Corp (NASDAQ:OPHT) weekly performance is 10.02%. On last trading day company shares ended up $45.11. Analysts mean target price for the company is $63.25. Ophthotech Corp (NASDAQ:OPHT) distance from 50-day simple moving average (SMA50) is 32.17%.
On May 13, 2014, Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) filed an amended and restated certificate of incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware in connection with the closing of the Company’s initial public offering of shares of its common stock. Alder Biopharmaceuticals Inc. (NASDAQ:ALDR) shares advanced 11.28% in last trading session and ended the day on $15.49. ALDR return on assets is -121.60%.
Vital Therapies, Inc. (NASDAQ:VTL), a biotherapeutic company developing a cell-based therapy targeting the treatment of acute liver failure, on 28 may announced financial results for the quarter ended March 31, 2014, and provided an update on recent operations. Vital Therapies reported a net loss for the quarter ended March 31, 2014 of $10.7 million and, after the accretion of redemption value and deemed dividends on our preferred stock, a net loss attributable to our common stockholders of $13.8 million. Vital Therapies Inc., (NASDAQ:VTL) shares moved up 26.34% in last trading session and was closed at $17.70, while trading in range of $13.99 – $19.36. Vital Therapies Inc. (NASDAQ:VTL) year to date (YTD) performance is 47.50%.
Applied Genetic Technologies Corporation (NASDAQ:AGTC), a clinical stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases announced that company management will present at two upcoming investor conferences. Jefferies Gene Therapy Summit on Monday, June 16, 2014 in Boston. Sue Washer, President and CEO will provide a corporate overview discussing the company’s lead programs in ophthalmology, including X-linked Retinoschisis (XLRS), Achromatopsia (ACHM) and X-linked Retinitis Pigmentosa (XLRP). Piper Jaffray GenomeRx Symposium on Monday, June 23, 2014 in New York. Ms. Washer will participate in panel discussions entitled “Ophthalmology: Seeing the Future of Gene Therapy Clearly”. Applied Genetic Technologies Corp (NASDAQ:AGTC) ended the last trading day at $22.16. Company weekly volatility is calculated as 20.83% and price to cash ratio as 11.14.Applied Genetic Technologies Corp (NASDAQ:AGTC) showed a positive weekly performance of 64.15%.
Jefferies Group assumed coverage on shares of China Biologic Products Inc. (NASDAQ:CBPO) in a report released on Thursday, TheFlyOnTheWall.com reports. The firm issued a buy rating and a $52.00 price objective on the stock. China Biologic Products Inc. (NASDAQ:CBPO) net profit margin is 33.90% and weekly performance is 4.44%. On last trading day company shares ended up $47.52. Analysts mean target price for the company is $51.00. China Biologic Products Inc. (NASDAQ:CBPO) distance from 50-day simple moving average (SMA50) is 22.78%.